In patients with HFrEF, SV initiation was titrated to the highest tolerable dosage. Patients were evaluated with portable apnea monitoring, echocardiography, and cardiopulmonary exercise testing at baseline and 3 months later.
Of a total of 18 patients, 9 (50%) had OA, 7 (39%) had CA, and 2 (11%) had normal breathing. SV therapy was related to a reduction in NT-pro BNP and an improvement in LV function after 3 months. Portable apnea monitoring revealed a significant decrease of the respiratory event index (REI) after treatment with SV (20 ± 23 events/h to 7 ± 7 events/h, p = 0.003). When subgrouping according to type of apneas, REI, and time spent below 90% saturation (T90) decreased in patients with CA and OA (all p < 0.05).
In this prospective study, SV treatment for 3 months in patients with CA and OA is associated with a significant decrease in REI.
方法:在HFrEF患者中,将SV起始滴定至最高耐受剂量。通过便携式呼吸暂停监测对患者进行评估,超声心动图,基线和3个月后的心肺运动试验。
结果:共有18名患者,9人(50%)患有OA,7人(39%)患有CA,2例(11%)呼吸正常。SV治疗与3个月后NT-proBNP降低和LV功能改善有关。便携式呼吸暂停监测显示,SV治疗后呼吸事件指数(REI)显着降低(20±23事件/h至7±7事件/h,p=0.003)。当根据呼吸暂停的类型进行分组时,REI,CA和OA患者在90%饱和度(T90)以下的时间减少(均p<0.05)。
结论:在这项前瞻性研究中,在CA和OA患者中,SV治疗3个月与REI的显着降低有关。